Floatz logo

Tulmimetostat

Ovarian Clear Cell Carcinoma

Novartis PharmaceuticalsSmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

15 Active assets in the Ovarian Clear Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
Genelux Corporation
Phase 3BB
Inno-206
Genelux Corporation
Phase 3BB
Docetaxel
Genelux Corporation
Phase 3B
Olvimulogene Nanivacirepvec
Genelux Corporation
Phase 3B
CIS-DIAMMINEDICHLOROPLATINUM II
Genelux Corporation
Phase 3B

View all 20 →

Same molecule, other indications

Tulmimetostat is also rated in:

metastatic prostate carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
T-cell non-Hodgkin lymphomaDormant
CC
Indicative ·
45 / 100
View asset →
malignant mesotheliomaDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →